Skip Nav Destination

Issue Archive

Select Year

Issue

Volume 2, Issue 14

July 24 2018

In this Issue

BLOOD ADVANCES TALK
POINT-COUNTERPOINT
EXCEPTIONAL CASE REPORT
STIMULUS REPORT
CLINICAL TRIALS AND OBSERVATIONS
HEMATOPOIESIS AND STEM CELLS
IMMUNOBIOLOGY AND IMMUNOTHERAPY
MYELOID NEOPLASIA
THROMBOSIS AND HEMOSTASIS
TRANSFUSION MEDICINE
TRANSPLANTATION

BLOOD ADVANCES TALK

Antiplatelet therapy in the management of atherothrombosis: recent clinical advances
Clinical Trials & Observations

Noel C. Chan,Jeffrey I. Weitz

View Articletitled, Antiplatelet therapy in the management of atherothrombosis: recent clinical advances

Supplemental data

POINT-COUNTERPOINT

The case for catheter-directed thrombolysis in selected patients with acute proximal deep vein thrombosis
Clinical Trials & Observations

Thita Chiasakul,Adam Cuker

This article has a companion Counterpoint by Poston and Garcia.

View Articletitled, The case for catheter-directed thrombolysis in selected patients with acute proximal deep vein thrombosis

The case against catheter-directed thrombolysis in patients with proximal deep vein thrombosis
Clinical Trials & Observations

Jacqueline N. Poston,David A. Garcia

This article has a companion Point by Chiasakul and Cuker.

View Articletitled, The case against catheter-directed thrombolysis in patients with proximal deep vein thrombosis

EXCEPTIONAL CASE REPORT

Sequential allogeneic and autologous CAR-T–cell therapy to treat an immune-compromised leukemic patient
Clinical Trials & Observations

Jian-Ping Zhang,Rui Zhang,Shih-Ting Tsao,Yu-Chen Liu,Xiaochuan Chen,Dao-Pei Lu,Paul Castillo,Lung-Ji Chang

View Articletitled, Sequential allogeneic and autologous CAR-T–cell therapy to treat an immune-compromised leukemic patient

STIMULUS REPORT

A phosphoproteomic signature in endothelial cells predicts vascular toxicity of tyrosine kinase inhibitors used in CML

Srila Gopal,Qing Lu,Joshua J. Man,Wendy Baur,Sitara P. Rao,Lev Litichevskiy,Malvina Papanastasiou,Amanda L. Creech,Katherine C. DeRuff,James Mullahoo,Adam Officer,Shawn B. Egri,Desiree Davison,Jacob D. Jaffe,Iris Z. Jaffe

View Articletitled, A phosphoproteomic signature in endothelial cells predicts vascular toxicity of tyrosine kinase inhibitors used in CML

Supplemental data

CLINICAL TRIALS AND OBSERVATIONS

Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance)
Clinical Trials & Observations

John C. Byrd,Amy S. Ruppert,Nyla A. Heerema,Alese E. Halvorson,Eva Hoke,Mitchell R. Smith,John E. Godwin,Stephen Couban,Todd A. Fehniger,Michael J. Thirman,Martin S. Tallman,Frederick R. Appelbaum,Richard M. Stone,Sue Robinson,Julie E. Chang,Sumithra J. Mandrekar,Richard A. Larson

View Articletitled, Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance)

Supplemental data

Prediction of cardiovascular disease among hematopoietic cell transplantation survivors
Clinical Trials & Observations

Saro H. Armenian,Dongyun Yang,Jennifer Berano Teh,Liezl C. Atencio,Alicia Gonzales,F. Lennie Wong,Wendy M. Leisenring,Stephen J. Forman,Ryotaro Nakamura,Eric J. Chow

View Articletitled, Prediction of cardiovascular disease among hematopoietic cell transplantation survivors

Supplemental data

HEMATOPOIESIS AND STEM CELLS

CLT030, a leukemic stem cell–targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia

Ying-Ping Jiang,Bob Y. Liu,Quan Zheng,Swapna Panuganti,Ruoying Chen,Jianyu Zhu,Madhavi Mishra,Jianqing Huang,Trang Dao-Pick,Sharmili Roy,XiaoXian Zhao,Jeffrey Lin,Gautam Banik,Eric D. Hsi,Ramkumar Mandalam,Jagath R. Junutula

View Articletitled, CLT030, a leukemic stem cell–targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia

Supplemental data

IMMUNOBIOLOGY AND IMMUNOTHERAPY

TNP-470 skews DC differentiation to Th1-stimulatory phenotypes and can serve as a novel adjuvant in a cancer vaccine

Derek Hoi-Hang Ho,Roger Hoi-Fung Wong

View Articletitled, TNP-470 skews DC differentiation to Th1-stimulatory phenotypes and can serve as a novel adjuvant in a cancer vaccine

Supplemental data

TCF1 expression marks self-renewing human CD8⁺ T cells

Radomir Kratchmarov,Arthur M. Magun,Steven L. Reiner

View Articletitled, TCF1 expression marks self-renewing human CD8<sup>+</sup> T cells

MYELOID NEOPLASIA

The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort
Clinical Trials & Observations

Maximilian Stahl,Michelle DeVeaux,Theo de Witte,Judith Neukirchen,Mikkael A. Sekeres,Andrew M. Brunner,Gail J. Roboz,David P. Steensma,Vijaya R. Bhatt,Uwe Platzbecker,Thomas Cluzeau,Pedro H. Prata,Raphaël Itzykson,Pierre Fenaux,Amir T. Fathi,Alexandra Smith,Ulrich Germing,Ellen K. Ritchie,Vivek Verma,Aziz Nazha,Jaroslaw P. Maciejewski,Nikolai A. Podoltsev,Thomas Prebet,Valeria Santini,Steven D. Gore,Rami S. Komrokji,Amer M. Zeidan

View Articletitled, The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort

THROMBOSIS AND HEMOSTASIS

Professional illustration by Patrick Lane, ScEYEnce Studios.

HLA-DRB1–factor VIII binding is a risk factor for inhibitor development in nonsevere hemophilia: a case-control study

Christine L. Kempton,Amanda B. Payne

View Articletitled, HLA-DRB1–factor VIII binding is a risk factor for inhibitor development in nonsevere hemophilia: a case-control study

Significant gynecological bleeding in women with low von Willebrand factor levels
Clinical Trials & Observations

Michelle Lavin,Sonia Aguila,Niall Dalton,Margaret Nolan,Mary Byrne,Kevin Ryan,Barry White,Niamh M. O’Connell,Jamie M. O’Sullivan,Jorge Di Paola,Paula D. James,James S. O’Donnell

View Articletitled, Significant gynecological bleeding in women with low von Willebrand factor levels

Supplemental data

Gene therapy in hemophilia A: a cost-effectiveness analysis

Nicoletta Machin,Margaret V. Ragni,Kenneth J. Smith

View Articletitled, Gene therapy in hemophilia A: a cost-effectiveness analysis

TRANSFUSION MEDICINE

Platelet transfusions improve hemostasis and survival in a substudy of the prospective, randomized PROPPR trial
Clinical Trials & Observations

Jessica C. Cardenas,on behalf of the PROPPR Study Group,Xu Zhang,on behalf of the PROPPR Study Group,Erin E. Fox,on behalf of the PROPPR Study Group,Bryan A. Cotton,on behalf of the PROPPR Study Group,John R. Hess,on behalf of the PROPPR Study Group,Martin A. Schreiber,on behalf of the PROPPR Study Group,Charles E. Wade,on behalf of the PROPPR Study Group,John B. Holcomb,on behalf of the PROPPR Study Group

View Articletitled, Platelet transfusions improve hemostasis and survival in a substudy of the prospective, randomized PROPPR trial

Supplemental data

TRANSPLANTATION

A novel predictive approach for GVHD after allogeneic SCT based on clinical variables and cytokine gene polymorphisms
Clinical Trials & Observations

Carolina Martínez-Laperche,Elena Buces,M. Carmen Aguilera-Morillo,Antoni Picornell,Milagros González-Rivera,Rosa Lillo,Nazly Santos,Beatriz Martín-Antonio,Vicent Guillem,José B. Nieto,Marcos González,Rafael de la Cámara,Salut Brunet,Antonio Jiménez-Velasco,Ildefonso Espigado,Carlos Vallejo,Antonia Sampol,José María Bellón,David Serrano,Mi Kwon,Jorge Gayoso,Pascual Balsalobre,Álvaro Urbano-Izpizua,Carlos Solano,David Gallardo,José Luis Díez-Martín,Juan Romo,Ismael Buño,on behalf of the GVHD/Immunotherapy Committee of the Spanish Group for Hematopoietic Transplantation

View Articletitled, A novel predictive approach for GVHD after allogeneic SCT based on clinical variables and cytokine gene polymorphisms

Supplemental data

In silico prediction of nonpermissive HLA-DPB1 mismatches in unrelated HCT by functional distance

Esteban Arrieta-Bolaños,Pietro Crivello,Bronwen E. Shaw,Kwang Woo Ahn,Hai-Lin Wang,Michael R. Verneris,Katharine C. Hsu,Joseph Pidala,Stephanie J. Lee,Katharina Fleischhauer,Stephen R. Spellman

View Articletitled, In silico prediction of nonpermissive HLA-DPB1 mismatches in unrelated HCT by functional distance

Supplemental data

Cover Image

Cover Image

COVER FIGURE
A schematic diagram of CLT030 (CLL1-ADC) antibody-drug conjugate (ADC). The D212 linker-payload is the D211 payload with a cleavable Val-Ala linker, PEG-8 spacer, and maleimide functional group to conjugate the linker-payload to reactive thiol groups on the antibody. The D212 linker-payload is conjugated to engineered cysteine residues of anti-CLL1 antibody, resulting in a drug-to-antibody ratio of 2. See the article by Jiang et al.
Front Matter
Editorial Board

All Issues

Advertisement intended for health care professionals

Email alerts

Continuous Publishing Alert

New Journal Content Alert

Latest
Most Read
Most Cited

Time to revisit reduced-dose radiotherapy for PCNSL?

Lin A, Brown S, Chinapen S, et al. Patterns of CMV infection after letermovir withdrawal in recipients of posttransplant cyclophosphamide–based transplant. Blood Adv. 2023;7(23):7153-7160.

Jalink M, Jacobs CF, Khwaja J, et al. Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease. Blood Adv. 2024;8(11):2622-2634.

Epigenetic features support the diagnosis of B-cell prolymphocytic leukemia and identify 2 clinicobiological subtypes

Retreatment of multiple myeloma with previously refractory drugs

Advertisement intended for health care professionals

Table of Contents

BLOOD ADVANCES TALK

Antiplatelet therapy in the management of atherothrombosis: recent clinical advances
Clinical Trials & Observations

POINT-COUNTERPOINT

The case for catheter-directed thrombolysis in selected patients with acute proximal deep vein thrombosis
Clinical Trials & Observations

The case against catheter-directed thrombolysis in patients with proximal deep vein thrombosis
Clinical Trials & Observations

EXCEPTIONAL CASE REPORT

Sequential allogeneic and autologous CAR-T–cell therapy to treat an immune-compromised leukemic patient
Clinical Trials & Observations

STIMULUS REPORT

A phosphoproteomic signature in endothelial cells predicts vascular toxicity of tyrosine kinase inhibitors used in CML

CLINICAL TRIALS AND OBSERVATIONS

Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance)
Clinical Trials & Observations

Prediction of cardiovascular disease among hematopoietic cell transplantation survivors
Clinical Trials & Observations

HEMATOPOIESIS AND STEM CELLS

CLT030, a leukemic stem cell–targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia

IMMUNOBIOLOGY AND IMMUNOTHERAPY

TNP-470 skews DC differentiation to Th1-stimulatory phenotypes and can serve as a novel adjuvant in a cancer vaccine

TCF1 expression marks self-renewing human CD8⁺ T cells

MYELOID NEOPLASIA

The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort
Clinical Trials & Observations

THROMBOSIS AND HEMOSTASIS

HLA-DRB1–factor VIII binding is a risk factor for inhibitor development in nonsevere hemophilia: a case-control study

Significant gynecological bleeding in women with low von Willebrand factor levels
Clinical Trials & Observations

Gene therapy in hemophilia A: a cost-effectiveness analysis

TRANSFUSION MEDICINE

Platelet transfusions improve hemostasis and survival in a substudy of the prospective, randomized PROPPR trial
Clinical Trials & Observations

TRANSPLANTATION

A novel predictive approach for GVHD after allogeneic SCT based on clinical variables and cytokine gene polymorphisms
Clinical Trials & Observations

In silico prediction of nonpermissive HLA-DPB1 mismatches in unrelated HCT by functional distance

Email alerts

ASH Publications

American Society of Hematology

Issue Archive

Table of Contents

BLOOD ADVANCES TALK

Antiplatelet therapy in the management of atherothrombosis: recent clinical advances Clinical Trials & Observations

POINT-COUNTERPOINT

The case for catheter-directed thrombolysis in selected patients with acute proximal deep vein thrombosis Clinical Trials & Observations

The case against catheter-directed thrombolysis in patients with proximal deep vein thrombosis Clinical Trials & Observations

EXCEPTIONAL CASE REPORT

Sequential allogeneic and autologous CAR-T–cell therapy to treat an immune-compromised leukemic patient Clinical Trials & Observations

STIMULUS REPORT

A phosphoproteomic signature in endothelial cells predicts vascular toxicity of tyrosine kinase inhibitors used in CML

CLINICAL TRIALS AND OBSERVATIONS

Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance) Clinical Trials & Observations

Prediction of cardiovascular disease among hematopoietic cell transplantation survivors Clinical Trials & Observations

HEMATOPOIESIS AND STEM CELLS

CLT030, a leukemic stem cell–targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia

IMMUNOBIOLOGY AND IMMUNOTHERAPY

TNP-470 skews DC differentiation to Th1-stimulatory phenotypes and can serve as a novel adjuvant in a cancer vaccine

TCF1 expression marks self-renewing human CD8+ T cells

MYELOID NEOPLASIA

The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort Clinical Trials & Observations

THROMBOSIS AND HEMOSTASIS

HLA-DRB1–factor VIII binding is a risk factor for inhibitor development in nonsevere hemophilia: a case-control study

Significant gynecological bleeding in women with low von Willebrand factor levels Clinical Trials & Observations

Gene therapy in hemophilia A: a cost-effectiveness analysis

TRANSFUSION MEDICINE

Platelet transfusions improve hemostasis and survival in a substudy of the prospective, randomized PROPPR trial Clinical Trials & Observations

TRANSPLANTATION

A novel predictive approach for GVHD after allogeneic SCT based on clinical variables and cytokine gene polymorphisms Clinical Trials & Observations

In silico prediction of nonpermissive HLA-DPB1 mismatches in unrelated HCT by functional distance

Cover Image

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only

Antiplatelet therapy in the management of atherothrombosis: recent clinical advances
Clinical Trials & Observations

The case for catheter-directed thrombolysis in selected patients with acute proximal deep vein thrombosis
Clinical Trials & Observations

The case against catheter-directed thrombolysis in patients with proximal deep vein thrombosis
Clinical Trials & Observations

Sequential allogeneic and autologous CAR-T–cell therapy to treat an immune-compromised leukemic patient
Clinical Trials & Observations

Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance)
Clinical Trials & Observations

Prediction of cardiovascular disease among hematopoietic cell transplantation survivors
Clinical Trials & Observations

TCF1 expression marks self-renewing human CD8⁺ T cells

The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort
Clinical Trials & Observations

Significant gynecological bleeding in women with low von Willebrand factor levels
Clinical Trials & Observations

Platelet transfusions improve hemostasis and survival in a substudy of the prospective, randomized PROPPR trial
Clinical Trials & Observations

A novel predictive approach for GVHD after allogeneic SCT based on clinical variables and cytokine gene polymorphisms
Clinical Trials & Observations